IN8bio, a clinical-stage biopharmaceutical company, focuses on gamma-delta T cell product candidates for solid and liquid tumors. These T cells, naturally differentiating between healthy and diseased tissue, act as a bridge between innate and adaptive immunity, contributing to tumor killing, immune cell recruitment, and activation. IN8bio utilizes its DeltEx platform, employing allogeneic, autologous, iPSC, and genetically modified cell therapies. With expertise in gamma-delta T cell biology and proprietary genetic engineering, the company aims to identify and eradicate tumor cells.